AAN 2016 Cerebrovascular Disease

Durlaza Shows Sustained Antiplatelet Effects Over 24 Hours in Patients With T2DM

By April 20, 2016

Durlaza, an extended-release aspirin formulation, provides "sustained antiplatelet effects over 24 hours" in patients with type 2 diabetes mellitus (T2DM).

Clopidogrel: Antiplatelet of Choice in Smokers for Secondary Stroke Prevention?

By April 20, 2016

For both smokers and nonsmokers, adding clopidogrel to aspirin therapy is associated with a reduced risk of second stroke in the 90 days following a stroke or high-risk transient ischemic attack (TIA)—but that association is much stronger among smokers

Droxidopa Effective, Safe for Symptomatic NOH Across Age Groups

By April 20, 2016

Use of the norepinephrine oral prodrug, droxidopa, for the treatment of symptomatic neurogenic orthostatic hypotension is effective and "generally well tolerated across a range of ages," including in those 75 years and older.

AAN 2016 Seizure Disorders

Verapamil: No Benefit as AED Adjuvant in Reducing Seizure Frequency

By April 21, 2016

Verapamil adjuvant therapy showed no benefit versus placebo in patients with refractory epilepsy on standard antiepileptic drug (AED) treatment

Researchers Detail Time to Switch or Add-on for Patients on First-line AED

By April 21, 2016

Most patients on first-line anti-epileptic drug (AED) monotherapy continue initial treatment for nearly 1.5 years, according to a retrospective database study reported at the 68th AAN Annual Meeting.

Qudexy XR Carries Few Neurocognitive Side Effects for Refractory POS Patients

By April 20, 2016

Individual neurocognitive treatment-emergent adverse events (TEAEs) appear to be relatively infrequent among patients administered USL255 (Qudexy® XR [topiramate] extended-release capsules) for refractory partial-onset seizures (POS).

AAN 2016 Multiple Sclerosis

Lower ARR, Higher PROs Seen After Glatiramer Acetate to DMF Switch

By April 21, 2016

DMF was associated with lower annualized relapse rates (ARR) and improvement on patient reported outcomes (PROs) in patients with relapsing multiple sclerosis (RMS) who switch to DMF following suboptimal response to glatiramer acetate (GA).

Glatiramer Acetate to Fingolimod Switch Might Reduce MS Relapse Rates

By April 21, 2016

Patients with relapsing-remitting multiple sclerosis (MS) had fewer relapses after switching from glatiramer acetate to fingolimod versus remaining on the injectable disease-modifying therapy

Does DMF Cut Multiple Sclerosis-Related Workplace Productivity Decline?

By April 21, 2016

Delayed-release dimethyl fumarate (DMF) is associated with better control of multiple sclerosis (MS)-associated declines in work productivity than the injectable platform therapies

AAN 2016 Neurodegenerative Disease

Peri-op Rivastigmine Patch Reduces Post-op Delirium in Elderly With Dementia Risk

By April 21, 2016

In elderly patients with cognitive dysfunction undergoing surgery for hip fracture, perioperative application of the rivastigmine patch reduced incidence postoperative delirium.

IncobotulinumtoxinA Injections in Hand, Forearm Improve Parkinson's Tremor

By April 21, 2016

IncobotulinumtoxinA injections customized by site and dose improved hand and forearm tremor symptoms patients with Parkinson's disease without increasing hand weakness

Levodopa-Carbidopa Intestinal Gel Well Tolerated in East Asians with Advanced PD

By April 20, 2016

Levodopa-carbidopa intestinal gel is safe and effective in Japanese, Taiwanese, and Korean patients with advanced Parkinson's disease

AAN 2016 General News

Ext-Rel Molindone Linked to Reduced Aggression in Children With ADHD

By April 21, 2016

An extended release formulation of molindone shows promise as an adjunctive treatment for refractory impulsive aggression among children administered stimulant monotherapy for ADHD.

Higher Rates of Total Migraine Freedom Observed with Intranasal vs. Oral Sumatriptan

By April 21, 2016

Treatment of acute migraine with AVP-825, an investigational Breath-Powered Bi-Directional intranasal delivery system containing sumatriptan powder 22mg, resulted in higher rates of total migraine freedom.

Deflazacort, Prednisone Improved Biomarkers of Muscle Breakdown in Boys With DMD

By April 20, 2016

Deflazacort and prednisone improved biomarkers of muscle breakdown versus placebo in boys with Duchenne muscular dystrophy, according to results of a randomized Phase 3 study reported at the 68th AAN Annual Meeting.